ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.
Baystreet.ca News Commentary
VANCOUVER, BC, Jan. 19, 2026 /PRNewswire/ — The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE: MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE: PM), Celsius Holdings (NASDAQ: CELH), USANA Health Sciences (NYSE: USNA), and Medifast (NYSE: MED).
Den vollständigen Artikel hier lesen
